Epigenetics in metabolic dysfunction-associated steatohepatitis

被引:0
|
作者
Zhang, Yanru [1 ,2 ]
Ding, Ruike [1 ,2 ]
Hu, Liangshuo [3 ]
Liu, Enqi [1 ,2 ]
Qu, Pengxiang [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, Xian 710061, Peoples R China
[2] Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
MASH; Epigenetics; Liver; DNA methylation; Histone modifications; Noncoding RNA; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; LIPID-METABOLISM; NONCODING RNAS; LIVER; EXPRESSION; DIET; HEPATOCYTES; FIBROSIS; INJURY;
D O I
10.1016/j.cellsig.2025.111684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease involving genetics, environment, and lifestyle, with the potential to progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Although the pathogenesis of MASH is not fully clear, increasing evidence has indicated that epigenetics plays an important role in the genesis and progression of MASH, during which, as drastic changes in metabolites, epigenetics undergo drastic changes. Roles of chromatin structure, chromatin accessibility, DNA methylation, histone modification, and non-coding RNAs were considered as bridges of pathogenic factors and MASH. In this review, the research progress on the epigenetics of MASH was summarized, and indepth research and therapeutic strategies based on epigenetics is expected to bring new hope to MASH patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
    Loomba, Rohit
    Hartman, Mark L.
    Lawitz, Eric J.
    Vuppalanchi, Raj
    Boursier, Jerome
    Bugianesi, Elisabetta
    Yoneda, Masato
    Behling, Cynthia
    Cummings, Oscar W.
    Tang, Yuanyuan
    Brouwers, Bram
    Robins, Deborah A.
    Nikooie, Amir
    Bunck, Mathijs C.
    Haupt, Axel
    Sanyal, Arun J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04) : 299 - 310
  • [22] Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy
    Xu, Fenghua
    Zhao, Shoujie
    Zhu, Yejing
    Zhu, Jun
    Kong, Lingyang
    Li, Huichen
    Ma, Shouzheng
    Wang, Bo
    Qu, Yongquan
    Tian, Zhimin
    Zhao, Junlong
    Liu, Lei
    LIFE METABOLISM, 2024, 3 (06):
  • [23] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (03) : 171 - 189
  • [24] Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review
    Ghazanfar, Haider
    Javed, Nismat
    Qasim, Abeer
    Zacharia, George Sarin
    Ghazanfar, Ali
    Jyala, Abhilasha
    Shehi, Elona
    Patel, Harish
    CANCERS, 2024, 16 (06)
  • [25] Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis
    Lai, Michelle
    Dillon, Simon T.
    Gu, Xuesong
    Morhardt, Tina L.
    Xu, Yuyan
    Chan, Noel Y.
    Xiong, Beibei
    Can, Handan
    Ngo, Long H.
    Jin, Lina
    Zhang, Xuehong
    Moreira, Claudia C.
    Leite, Nathalie C.
    Villela-Nogueira, Cristiane A.
    Otu, Hasan H.
    Schattenberg, Joern M.
    Schuppan, Detlef
    Afdhal, Nezam H.
    Libermann, Towia A.
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (12)
  • [26] Pyroptosis and gasdermins-Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
    Stoess, Christian
    Leszczynska, Aleksandra
    Kui, Lin
    Feldstein, Ariel E.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [27] Metabolic dysfunction-associated steatohepatitis exhibits sex differences in people with HIV
    Kablawi, Dana
    Milic, Jovana
    Thomas, Tyler
    Tadjo, Thierry Fotsing
    Cinque, Felice
    Elgretli, Wesal
    Gioe, Claudia
    Lebouche, Bertrand
    Tsochatzis, Emmanuel
    Finkel, Jemima
    Bhagani, Sanjay
    Cascio, Antonio
    Guaraldi, Giovanni
    Mazzola, Giovanni
    Saeed, Sahar
    Sebastiani, Giada
    HIV MEDICINE, 2024, 25 (11) : 1259 - 1269
  • [28] Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis
    Pulaski, Hanna
    Harrison, Stephen A.
    Mehta, Shraddha S.
    Sanyal, Arun J.
    Vitali, Marlena C.
    Manigat, Laryssa C.
    Hou, Hypatia
    Christudoss, Susan P. Madasu
    Hoffman, Sara M.
    Stanford-Moore, Adam
    Egger, Robert
    Glickman, Jonathan
    Resnick, Murray
    Patel, Neel
    Taylor, Cristin E.
    Myers, Robert P.
    Chung, Chuhan
    Patterson, Scott D.
    Sejling, Anne-Sophie
    Minnich, Anne
    Baxi, Vipul
    Subramaniam, G. Mani
    Anstee, Quentin M.
    Loomba, Rohit
    Ratziu, Vlad
    Montalto, Michael C.
    Anderson, Nick P.
    Beck, Andrew H.
    Wack, Katy E.
    NATURE MEDICINE, 2025, 31 (01) : 315 - 322
  • [29] Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
    Saeed, Anzel
    Rai, Kuldeep Dalpat
    Saeed, Muzammil
    LIVER RESEARCH, 2024, 8 (03) : 193 - 194
  • [30] Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis
    Yashaswini, Chittampalli N.
    Qin, Tianyue
    Bhattacharya, Dipankar
    Amor, Corina
    Lowe, Scott
    Lujambio, Amaia
    Wang, Shuang
    Friedman, Scott L.
    JOURNAL OF HEPATOLOGY, 2024, 81 (02) : 207 - 217